For how we live.
A national survey of more than 120,000 children put combined prevalence at 5.4% and heavy-intensity infection below WHO's 1% elimination threshold, after ten years of preventive chemotherapy.
Measles incidence edged up and rubella more than doubled across 22 countries in 2023–2024, with outbreaks in Yemen, Iraq and Afghanistan driving the trend as second-dose coverage stalled.
Analysing 32,294 viral sequences from 16,428 people, Swiss researchers found 23 fast-growing clusters drove a third of recent transmission growth — evidence molecular surveillance could target the remaining chains.
A modelling study finds South Africa's selective birth-dose policy is efficient per infection averted, but giving every newborn a dose would prevent the most disease and be the most cost-effective overall.
Bangladesh was validated in 2023 as the first country to eliminate visceral leishmaniasis as a public health problem; India is nearing the same threshold, even as post-kala-azar skin cases climb.
Human cases are a rounding error against the 3.5 million of the 1980s. But 684 animal infections, most of them dogs in Chad, now stand between the programme and eradication.
WHO validated Bhutan's elimination of dog-transmitted human rabies, a disease almost always fatal once symptoms appear. The country has recorded zero such deaths since June 2023.
WHO validated Timor-Leste's elimination of trachoma, the last suspected focus in its South-East Asia Region. A 2025 survey of 4,949 young children found no transmission requiring intervention.
National surveillance shows no decline from 2020 to 2024, with one in five patients already disabled at diagnosis — a marker of late detection even as the global burden falls.
Adult TB incidence and mortality are projected to fall 46% and 54% by 2030, short of the 80% and 90% goals. Wider symptom-driven testing matters most to closing the gap, the analysis suggests.
ECDC data show near-zero hepatitis B in under-fives and vertical transmission below 2%, alongside five million chronic infections and only seven countries meeting the harm-reduction benchmark.
An analysis of 15 years of case data from Altamira, in the Xingu Basin, finds forest edge and local population size — not climate — explained where transmission returned.
A peer-reviewed account traces the mass screening and tsetse-fly control that cut gambiense sleeping sickness below one case per 10,000 in endemic areas — the threshold WHO validated in January 2025.
The surveillance behind the WHO-verified milestone is now published: no infective blackflies at any monitored site, and no infection among 16,406 children tested.
WHO and CDC estimate cases climbed about 20% in a single year, and the number of countries hit by large or disruptive outbreaks jumped from 36 to 57 — while global first-dose coverage stayed flat.
WHO validated Egypt as the 27th country to eliminate trachoma as a public health problem. Its programme began in 2002; the disease still blinds or impairs about 1.9 million people elsewhere.